aesthetic and dermatology trends in global market
The global aesthetic medicine
market is expected to reach USD 11.9 billion by 2022, the market growth
mainly includes in aging population, increasing disposable income, and
increased awareness about cosmetic surgeries. The research analyst predicts the
global medical aesthetics market to grow steadily at a CAGR of approximately
10.8% by 2020. The invasive aesthetic procedures are set to grow at a CAGR of
4.3%, while non-invasive procedures will grow at a CAGR of 4.5% over the coming
five years. Recent advances in technologies, especially in the laser-based
medical aesthetic segment, are expected to drive market growth during the
forecast period. Medical laser technologies such as high intensity focused
ultrasound, transdermal focused ultrasound, and others are rapidly gaining
popularity among the populace as they are non-invasive and help in fat
reduction. The North American market accounts for about 45% of the global
market. However, the dominance of the U.S. is shifting towards Asia,
particularly in the energy- based devices segment. Asia is regarded
as the next frontier and the number of physicians and clinics
in China and India has been steadily rising, along with
medical tourism in the region. In the injectables and devices category, the
E.U. occupies the second position behind the U.S. Brazil continues to
be a strong market for aesthetics and cosmetic procedures. Allergan, Inc.
(Ireland), Cynosure, Inc. (U.S.), Lumenis Ltd. (Israel), Mentor Worldwide LLC
(U.S PhotoMedex, Inc. (U.S.), Solta Medical, Inc. (U.S), Syneron Medical, Ltd.
(Israel), Galderma S.A. (Switzerland), and ZELTIQ Aesthetics, Inc. (U.S.)
are some of the main players in the global medical aesthetics market.
Product-based segmentation of the medical
aesthetics market
Dermatological
conditions are one of the most common types of disorders worldwide, and
approximately one-third of the US population suffers from at least one active
skin condition. For the past decades, the majority of the dermatology market
has remained saturated with established products. However, the clinical and
commercial success of biologics in the treatment of psoriasis, as well as
advancements in the understanding of the disease pathways of many
dermatological conditions, have led to a renewed interest from pharmaceutical
companies in the dermatology market, and subsequently the emergence of an
innovative pipeline.
This
report covers all dermatological disorders, but there is a particular focus on
three key diseases: atopic dermatitis, acne vulgaris and psoriasis, as these
conditions have the highest prevalence and the largest pipeline. The global
dermatology market was valued at $20.0 billion in 2015 and is projected to grow
at a considerable Compound Annual Growth Rate (CAGR) of 7.73%, reaching $33.7
billion in 2022. Key drivers of this growth will be the uptake of recently
approved premium biologics, as well as promising late-stage products that are
expected to be highly valuable.
The
dermatology market landscape is expected to change substantially with the
advent of promising novel pipeline products.
Overall,
there are 801 dermatology products in the pipeline, with biologics representing
37% of the pipeline, despite the fact that this molecule type represents only a
small fraction of the marketed products landscape.
For abstract submission: https://aestheticmedicine.dermatologymeeting.com/abstract-submission.php
For registration
details: https://aestheticmedicine.dermatologymeeting.com/registration.php
If you any queries
related to the conference, kindly email us at:
Comments
Post a Comment